In vitro neurology assays

Screen your lead candidate compounds using InnoSer’s in vitro neurology assays to progress to preclinical in vivo studies with confidence

Home » Neurology CRO Services » In vitro neurology assays

In vitro neurology assays are carried out using primary and/or immortalized rodent and/or human (co)-cultures to screen and identify candidate compounds for further lead selection via preclinical in vivo research. Cultures of cells found within the central nervous system (CNS) such as microglial and neuronal cells allow you to evaluate the mechanism of action and efficacy of your novel investigational compounds in an in vitro setting for neurotoxicity, neurodegeneration/neuroprotection or neuroinflammation assessment. 

InnoSer offers preclinical contract research services using a wide range of commercially available cell lines, primary rodent cells as well as ex vivo brain slices. Leverage our validated in vitro neurodegeneration assays or partner with our scientists to set up and validate custom assays. After an initial disease model induction phase (using disease-associated proteins, protein aggregates. and chemical toxins), cell cultures are treated with your novel investigational compounds of choice to determine efficacy. In vitro neurodegenerative disease assays can be performed before or in conjunction with running in vivo preclinical studies (PK/PD profiling or efficacy studies in InnoSer’s mouse models of neurodegenerative diseases).  

Developing new, safe, and efficacious therapies is an extremely intricate process. As a preclinical neurology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical neurology studies to InnoSer, you gain access to our in vitro and in vivo neurology drug development portfolio.  

CRO services with in vitro neurodegenerative assays that InnoSer offers:  

  • Wide range of neurology in vitro assays in (co)-cultures of rodent primary cells e.g., ex vivo brain slides, and immortalized rodent and human cell lines of neuronal and microglial cells (e.g. SHSY5Y, HCM3). 
  • Neurodegenerative disease-associated proteins, chemical induction of disease phenotype or transgenic cell lines 
  • Wide range of assays (e.g., aggregation, phagocytosis, neurotoxicity and neuroinflammation) 
  • Custom model and assay validation. 

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key in vitro neurology assays that InnoSer offers: 

  • Neuroinflammation in vitro assay
  • Phagocytosis in vitro assay
  • Aggregation in vitro assay using disease-associated proteins (e.g., recombinant amyloid-beta proteins) 
  • Neurotoxicity/ cell viability in vitro assay
  • Apoptosis and necrosis in vitro assay
  • Cell metabolism in vitro assay
  • Live cell imaging (IncuCyte)   
  • Immunocytochemistry 
  • Analysis of NO, ROS, cytokines 
  • Neurodegeneration mesoscale discovery (MSD) or ELISA panels (Aβ38, Aβ40, Aβ42, APP, α-Synuclein Contactin-2/TAG-1, Neprilysin, Neuronal pentraxin-1, Tau) 
  • Neurodegenerative disease modeling in vitro using disease-related peptides (e.g., amyloid-β fibrils, MBP, α-synuclein, etc.)  
  • Stimulus–induced (e.g., LPS, IL-13, Rotenone, etc.) neurodegenerative disease modeling in vitro
  • Neurotoxin-induced (e.g., H2O2, 6-OHDA, Rotenone, etc.) neurodegenerative disease modeling in vitro 

Example data featuring in vitro neurology assays:  

    The people behind your research

    Jolien Beekens, PhD

    Jolien Beekens, PhD, Neurology Study Director

    With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.

    Thomas Vogels, PhD Neurology study director InnoSer

    Thomas Vogels, PhD, Neurology Study Director

    Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.

    Related model options

    Neurology Platform Overview

    Highly relevant neurology models to facilitate preclinical drug development

    Alzheimer's Disease Mouse Models

    InnoSer offers APP transgenic mice as well as transgenic Tau and Tau seeding models using recombinant and/or patient-derived seeds. 

    Parkinson's Disease Mouse Models

    InnoSer offers MPTP mouse model, transgenic alpha-synuclein, or seeding alpha-synuclein mouse models using recombinant and/or patient-derived seeds. 

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Ready to work with a CRO that’s as committed as you are?

     

    Join us in delivering impactful studies that bring therapies to patients sooner.